

27<sup>th</sup> January 2021

(1) BSE Limited  
Listing Department  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

(2) National Stock Exchange of India Ltd  
Listing Department  
Exchange Plaza, 5<sup>th</sup> floor,  
Plot no. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai - 400 051

**Scrip Code: 500087**

**Scrip Code: CIPLA EQ**

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG  
Societe Anonyme  
35A Boulevard Joseph II,  
L-1840 Luxembourg

**Sub: Press Release - Cipla champions its commitment to carbon neutrality with its 30 MW solar plant in Maharashtra**

Dear Sir / Madam,

Please find enclosed press release dated 27<sup>th</sup> January 2021 for the captioned subject.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking you,

**Yours faithfully,  
For Cipla Limited**

**Rajendra Chopra  
Company Secretary**

Encl.as above

Prepared by: Mandar Kurghode

Press Release

## **Cipla champions its commitment to carbon neutrality with its 30 MW solar plant in Maharashtra**

*Cipla is the first pharmaceutical company in Maharashtra with group captive open access solar power project of this scale*

**India; January 27, 2021:** Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as "Cipla" today announced that it has set up a 30 MW solar group captive project in Tuljapur, Maharashtra. Spread across 115 acres, the solar project has been commissioned in partnership with AMP Energy India, and is one of the largest solar open access projects in the state set up by a corporate.

This is in line with the Company's ESG initiatives aimed at developing a holistic sustainability road map for the future. By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.

The project will support the Company's green energy requirements for its manufacturing units at Kurkumbh and Patalganga in Maharashtra. It will also help the Company avoid carbon dioxide emissions by as much as 35,000 tonnes of carbon dioxide equivalent (tCO<sub>2</sub>e) annually over its project life of 25 years.

In Aug 2018, Cipla successfully implemented a third party solar open access through a long term power purchase agreement in Karnataka that helped replace 90% of energy sourcing for the Company's manufacturing units in Virgonagar and Bommsandra to renewable power.

Speaking on the occasion, **Mr. Kedar Upadhye, President and Global CFO, Cipla**, said, "Sustainability is at the core of Cipla's DNA , and this solar power plant is a true reflection of our belief of contributing towards a greener environment. This project is testament to our relentless commitment to use cleaner and renewable sources of energy."

**Ms. Geena Malhotra, President and Global Head – Manufacturing Operations, Cipla**, commented, "The project aims to reduce our environmental footprint and create a positive social impact. We endeavour to continue growing the share of renewable energy across our sites with an aim to contribute to India's agenda of increasing energy generation from non-fossil fuel sources to 40% by 2030."

Since FY19, Cipla has added 48 MW of solar energy portfolio through various initiatives such as an on-site roof top or ground mounted solar under RESCO model, third party solar open access power purchase agreement, and group captive solar open access project.

In May 2019, Cipla had acquired a stake of 26 % in AMP Solar Power System Limited, a wholly owned subsidiary of AMP Solar Technology Private Limited and is a special purpose vehicle formed with an aim of setting up a captive solar project in Maharashtra.

**About Cipla:**

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT November' 20), 3rd largest in the pharma private market in South Africa (IQVIA MAT November'20), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit [www.cipla.com](http://www.cipla.com), or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

**For queries, please contact:****Corporate Communications**

Heena Kanal

E-Mail: [CorpComm@cipla.com](mailto:CorpComm@cipla.com)**Investor Relations**

Naveen Bansal

E-Mail: [Investor.Relations@cipla.com](mailto:Investor.Relations@cipla.com)